Ariad Pharmaceuticals has halted patient enrollment for clinical trials of its leukemia drug Iclusig in compliance with the FDA's decision to put the studies on partial hold. The move is in response to Phase II trial results showing that 12% of patients on Inclusig developed blood clots after 24 months and 6.2% experienced symptoms that could have led to heart damage. Ariad will reduce the dosage in the Phase III study and exclude patients who had a heart attack or stroke "to ameliorate the toxicity we are seeing and still retain the efficacy," company executives said.

Full Story:

Related Summaries